MicroFSMA (Microfluidic based platform for SeMen Analysis) put sperm on a chip built to mimic the female reproductive tract, so swimming behaviour could be watched and measured directly, cell by cell, instead of inferred.
Sperm motility is the main test clinicians use to diagnose male infertility, scored either by eye against the World Health Organization's protocol or by commercial Computer Assisted Semen Analysis (CASA) systems1. Both methods watch sperm swim in a plain dish, an environment nothing like the tract the cells actually navigate to reach the egg, guided there by chemotaxis, thermotaxis, and rheotaxis2.
Manual scoring is also slow3, and CASA results can shift when the same sample is re-screened4. Microfluidic chips offered a fix already proven in pieces: microchannels can track sperm motility as reliably as CASA5, and separately, other groups had used chips to study how sperm respond to chemical6 and thermal7 gradients. No one had put a standardised, user-friendly platform to work studying flow-driven swimming itself.
MicroFSMA deployed a microfluidic chip carrying a hydrostatic-pressure-driven flow, the tract's rheotaxis cue, then filmed and tracked how sperm actually move against it.
A height difference between reservoirs drives a controlled flow through the chip, the rheotaxis cue sperm swim against in the tract.
A computer program follows sperm heads and flagella across time-lapse footage, cell by cell.
Linking positions frame to frame turns swimming behaviour into hard numbers on motility and kinematics.
Left alone in a dish, a sperm cell swims a straight line with a symmetrical flagellar beat. Put it in a channel against a hydrostatic-pressure-driven flow, the rheotaxis cue sperm meet throughout the female tract, and a responsive cell switches to an asymmetric beat and traces a helical path upstream. Seeing that shift at all requires studying the cell somewhere the flow exists, which a plain dish never provides. MicroFSMA built exactly that:
MicroFSMA's real outcome went beyond its papers and its measurement platform: it led directly to the founding of Beezbiotech SAS in Rennes in 2021, at the close of the fellowship. An MSCA Individual Fellowship spinning out into a company is rare; most end with a publication, not a business. Getting there took Dr. Shiva Kant Shukla carrying the work single-handedly, from research to prototype to company, turning what looked like an impossible task into a working one.
Given the ethical significance of the field, MicroFSMA's results were shared with the wider community through selected magazine articles and a dedicated symposium at a scientific festival, alongside the usual academic channels.
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 842299.